About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, June 12th, 2017

The QualityStocks
Daily Stock List


Giggles N' Hugs, Inc. (GIGL)

OTCJournal, Tip.us, RedChip, StocksToBuyNow, SeriousTraders, SmallCap Network, Investor's Insight, RedChip, SmallCapVoice, and Money and Markets reported earlier on Giggles N' Hugs, Inc. (GIGL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Giggles N' Hugs, Inc. is the owner and operator of family-friendly restaurants. These restaurants bring together high-end, organic food with active, leading-edge play and entertainment for children. The Company features high-quality menus made from fresh and local foods. Established in 2010, Giggles N' Hugs is based in Los Angeles, California and lists on the OTC Markets’ OTCQB.

Each Giggles N' Hugs location offers an upscale, family-friendly atmosphere with a dedicated play area for children 10 and younger. The Company also features nightly entertainment. This includes magic shows, concerts, puppet shows, and face painting, and party packages for families.

Membership at Giggles N' Hugs comes with benefits. These include first access to its special kids’ events, monthly deals, and unlimited visits for the entire family.  The Company was voted the #1 birthday party place in Los Angeles, California by Nickelodeon. On addition, it was voted "Best Pizza in Los Angeles" by Nickelodeon. Furthermore, Giggles N' Hugs was listed best family & kid-friendly restaurants by CitySearch and GoCityKids. Giggles N' Hugs has locations in Century City, Topanga, and Glendale, California.

Recently, Giggles N’ Hugs announced that it engaged PacificShore Ventures to explore potential synergistic acquisition opportunities. PacificShore is a worldwide specialty finance and Mergers & Acquisitions (M&A) firm.

Joey Parsi, Chief Executive Officer, said, “Those that have followed Giggles N’ Hugs know that we have plans to develop and launch a full line of complementary merchandise under our growing brand. This relationship with PacificShore could help us jump-start this segment of our business. Acquisition targets that we plan to look at could include food companies, with established distribution, that expedite the launch of our frozen food line of pizzas, pastas, and other kids’ meals in which we infuse healthiness by pureeing vegetables and hiding it in kids’ favorite meals, alike to what California Pizza Kitchen and Wolfgang Puck have done with their frozen meals that are available at the local supermarket.”

Giggles N' Hugs is targeting companies that are cash flow positive and have minimum annual revenue of $5 million or more. PacificShore will work to identify and create target company profiles, introduce, initiate negotiations, and ultimately facilitate the closing of such potential companies and to introduce traditional banking relationships for Giggles N' Hugs to fund the acquisitions.

At the end of May, Giggles N’ Hugs announced that it signed a non-binding Letter of Intent (LOI) with City Scape trading (franchisee), a Bahrain-based hospitality company, to open up to two Giggles N’ Hugs franchise locations in Bahrain with additional locations to come if successful. With this master license agreement, Giggles N’ Hugs will receive up-front development fees for each location, and also a continuing royalty based on a percentage of monthly gross sales.

Giggles N' Hugs, Inc. (GIGL), closed Monday's trading session at $0.094, up 0.11%, on 624,677 volume with 65 trades. The average volume for the last 60 days is 2,260,787 and the stock's 52-week low/high is $0.0018/$0.26.

Surna, Inc. (SRNA)

Promotion Stock Secrets, Wall Street Mover, TopPennyStockMovers, Marketbeat, CFN Media Group, Cannabis Financial Network News, SmallCapVoice, Greenbackers, OTC Stock Review, DSR News, PHUB News, Actual Gains, Hot Stock Profits, PennyStockRumors.net, PricelessPennyStocks, Value Penny Stocks, Ascending Stocks, and Market Wire Stocks reported earlier on Surna, Inc. (SRNA), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Surna, Inc. develops, acquires, produces, and sells equipment for the legal marijuana industry. The Company develops innovative technologies and products to monitor, control, and address the energy and resource intensive nature of indoor cannabis cultivation. Surna’s mission is to acquire intellectual property (IP) and scalable operating companies in the nascent, legal marijuana industry with a focus on disruptive technology, equipment, and related support services. OTCQB-listed, Surna is based in Boulder, Colorado.

Surna is a technology business that engineers, manufactures, and distributes state-of-the art equipment and systems for Controlled Environment Agriculture (CEA). The Company currently specializes in commercial indoor cannabis cultivation. Its business model excludes the production or sale of marijuana. Surna develops ground-breaking technologies and products. These technologies and products monitor, control, or address the energy and resource intensive nature of indoor cannabis cultivation.

Surna’s objective is to dominate the infrastructure, growing, and support side of the international cannabis industry. The basis of its present revenue stream is on its primary product offerings - supplying industrial technology and products to commercial indoor cannabis grow facilities. Via its wholly-owned subsidiary, Hydro Innovations, Surna provides a comprehensive line of commercial and small business indoor agriculture equipment.

Surna has its signature water-cooled climate control platform. It has filed a provisional patent application covering enhancements to its proprietary Climate Control Systems and Methods used in indoor gardens. The patent covers an industrial process, which provides electricity, heating, and cooling while utilizing the resulting carbon-dioxide (CO2) produced as a nutrient for the plants.

Surna’s intention is to integrate this and other proprietary technology into a new, commercial-grade power-generating and environmental control system product. The system is undergoing design to provide a near zero waste energy alternative for the cannabis industry.

At the end of May, Surna announced the appointment of Mr. J. Taylor Simonton and Mr. Chris Bechtel as Independent Directors. The appointments fill two vacancies on the Board. Moreover, Surna announced the establishment of an Audit Committee. Messrs., Simonton and Bechtel, together with Mr. Timothy J. Keating, Surna’s Chairman of the Board and an Independent Director, were appointed to serve as members of the Audit Committee. Mr. Simonton was appointed as the Chair of the Audit Committee.

Surna, Inc. (SRNA), closed Monday's trading session at $0.12, up 1.69%, on 452,008 volume with 58 trades. The average volume for the last 60 days is 733,470 and the stock's 52-week low/high is $0.0725/$0.294.

Mikros Systems Corp. (MKRS)

Wall Street Mover, Promotion Stock Secrets, Marketbeat, Fast Money Alerts, Actual Gains, AddictivePennyStocks, PennyStockRumors.net, PricelessPennyStocks, PennyStockLocks, StockBomb, StockLockandLoad, ResearchOTC, StockRockandRoll, PennyStocks24, AwesomeStocks, Buzz Stocks, Chatter Box Stocks, OTCEquity, and OTPicks reported on Mikros Systems Corp. (MKRS), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Mikros Systems Corp. is a provider of advanced maintenance and monitoring solutions for mission-critical systems. The Company is an advanced technology enterprise that designs and manufactures specialized electronic systems for the Department of Defense. Its principal business is to pursue and obtain contracts from the Department of Homeland Security, the U.S. Navy, as well as other governmental authorities. The Company is based in Princeton, New Jersey, and has its Manufacturing and Depot Center in Largo, Florida.

Mikros Systems has developed, delivered, and installed military-grade equipment to Federal customers for over 30 years. Its capabilities include technology management, electronic systems engineering and integration, radar systems engineering, command, control, communications, computers and intelligence systems engineering, and communications engineering.

The Company produces advanced maintenance systems for the Navy. These include the ADEPT Maintenance Automation Workstation and the ADSSS Condition Based Maintenance system for the Littoral Combat Ship.  ADEPT systems are in use everyday for performance optimization of advanced radar systems.  

Mikros Systems’ Lifecycle Support capability is focused on ensuring the systematic interactions between Integrated Logistics Support (ILS), Depot, and Field Support activities are integrated to accomplish the highest levels of system readiness. The Company purchased certain software products, intellectual property (IP) and related assets from VSE Corp. The main software programs purchased by Mikros are the Prognostics Framework (PF) and Diagnostic Profiler (DP) programs.

The Diagnostic Profiler software is used globally by numerous multinational companies for optimized maintenance of diverse product lines. In addition, Diagnostic Profiler is used by the U.S. Air Force for depot test programs.

Prognostics Framework is used by the U.S. Army for many missile defense systems. These software products provide Mikros Systems with the opportunity to service commercial customers and additional Department of Defense customers outside the Navy.

Today, Mikros Systems announced that it received a second contract from the United States Navy for development of a new upgrade to the Company’s ADSSS® (ADEPT Distance Support Sensor Suite) product line. The new award increases existing funding from $1.5 million to $2 million.

This new variant of Mikros’ flagship Condition Based Maintenance (CBM) product will be applied to the Navy’s AN/SPG-62 radar, part of the mission-critical MK 99 Fire Control System. This will be the first time Mikros CBM technology, first introduced on the Littoral Combat Ship (LCS), has been applied to the Navy’s Aegis Weapons System in the surface combatant fleet. More than 300 radars are now installed on Navy cruisers and destroyers.

Mikros Systems Corp. (MKRS), closed Monday's trading session at $0.5255, up 11.81%, on 214,672 volume with 109 trades. The average volume for the last 60 days is 48,389 and the stock's 52-week low/high is $0.0667/$0.624.

Medicine Man Technologies, Inc. (MDCL)

The Street and CFN Media Group reported on Medicine Man Technologies, Inc. (MDCL), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Medicine Man Technologies, Inc. represents and licenses the cultivation and dispensary Intellectual Property (IP) of Medicine Man -  a well-respected Tier III operator in Colorado. Medicine Man Technologies provides cultivation consulting services for cannabis growing technologies and methodologies. The Company is one of the country’s foremost cannabis brand development and consulting enterprises.  Founded in 2014, Medicine Man Technologies is based in Denver, Colorado.

The Company works closely with industry-leading extraction partners. These partners provide the required licensing service support and formulations to help customers with their planned deployment of a successful processing facility. Medicine Man Technologies secured its first client/licensee in April 2014.

At present, Medicine Man Technologies has 28 active clients in 12 states and Puerto Rico. The Company is concentrating on working with clients to utilize its experience, technology, and training to help secure a license in states with newly emerging regulations. It is also concentrating on deploying its highly effective variable capacity constant harvest cultivation practices via its deployment of Cultivation MAX, and eliminating the liability of single grower dependence.

Additionally, Medicine Man is focusing on avoiding the costly mistakes typically made in start-up, and staying engaged with a growing team of licensees and partners that will 'share' the ever-improving experience and knowledge of the network. Furthermore, the Company is continuing the expansion of its Brands Warehouse concept.

Medicine Man Technologies also engages in retail operations of cannabis products. The Company also provides general business and referral management for other related service providers for its customers. It cultivates and sells through its parent company Medicine Man Denver, the largest cultivation/retail facility in Colorado.

Medicine Man’s risk-averse cannabis cultivation technology delivers consistent, high quality, high yield production within a clean-room style environment. The Company’s state-of-the art dispensary model ensures patients and consumers have safe and secure access to an assortment of medical and/or recreational cannabis products.

Last month, Medicine Man Technologies announced that it agreed to terms to acquire the Denver Consulting Group, LLC with offices in Denver, Colorado, and Portland, Oregon. The terms of the acquisition provide for Medicine Man Technologies to issue an aggregate of 2,258,065 shares of its Common Stock to the Members of Denver Consulting Group. 

Medicine Man Technologies, Inc. (MDCL), closed Monday's trading session at $1.4492, up 8.96%, on 28,388 volume with 38 trades. The average volume for the last 60 days is 25,659 and the stock's 52-week low/high is $1.26/$5.00.

Titan Medical, Inc. (TITXF)

OTC Markets Group, BullRally, CoolPennyStocks, HotOTC, MadPennyStocks, PennyStockVille, StockRich, and Sharemkt Tips reported earlier on Titan Medical, Inc. (TITXF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A medical device enterprise, Titan Medical, Inc. centers on the design, development, and commercialization of a robotic surgical system for application in minimally invasive surgery (MIS). Presently under development, the Company’s SPORT Surgical System includes a surgeon-controlled robotic platform, which features multi-articulating instruments for performing MIS procedures via a single port. Titan Medical has its corporate office in Toronto, Ontario. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Titan Medical’s surgical system includes a workstation that provides a surgeon with an advanced ergonomic interface to the robotic platform for controlling the instruments and also provides a 3D high-definition endoscopic view inside a patient's body. The design of the SPORT system is to enable surgeons to perform a wide-ranging set of general abdominal, gynecologic, urologic, and colorectal procedures.

The design of this system is for improved clinical capabilities, operating room efficiency, as well as hospital economics. The SPORT Surgical System provides access to underserved market segments, such as ambulatory surgery centers. Regarding Open Display, the 3D high definition 32-inch display offers a premier balance of surgical immersion and situational awareness in the Operating Room (OR).

The SPORT Surgical System is an innovative single incision robotic surgical system. It has undergone development based on clinical user needs and is covered by 14 patents and 37 pending applications.

The Company recently announced the completion of initial formative human factors studies for its SPORT single port robotic surgical system. Formative human factors studies involve the evaluation of prototypes by expert users that center on simulated task exercises critical to product safety. Titan Medical is planning to commercialize its single incision surgical system - first in Europe and then the United States.

Last week, Titan Medical announced the publication of European Patent No. EP2996613, titled, "Articulated Tool Positioner and System Employing Same." This patent describes the smooth and continuously curved articulation of a robotic instrument to position and orient an end-effector in multiple degrees of freedom.
The continuous curve architecture potentially provides a number of advantages. These include facilitating a central lumen, which extends through the instrument to provide an independent roll of the end-effector, and provision for a host of removable end-effectors. Corresponding patent applications are pending in many countries, including the United States and China.

Titan Medical, Inc. (TITXF), closed Monday's trading session at $0.1915, down 0.78%, on 1,841,129 volume with 407 trades. The average volume for the last 60 days is 332,996 and the stock's 52-week low/high is $0.1882/$0.697.


The QualityStocks
Company Corner


India Globalization Capital, Inc. (IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital, Inc. (NYSE: IGC). Today, India Globalization Capital, Inc. closed trading at $0.425, up 1.19%, on 289,677 volume with 617 trades. The stock’s average daily volume over the past 60 days is 328,763, and its 52-week low/high is $0.19/$0.80.

India Globalization Capital, Inc. is pleased to announce that it has entered into a definitive license agreement with the University of South Florida making IGC the exclusive licensee of the U.S. patent filing entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” By acquiring this patent filing, IGC is protecting a potential cannabis-based blockbuster treatment for America’s most expensive disease.

India Globalization Capital, Inc. (IGC) is a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions.

The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC's patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its focus on combination therapy it can formulate and commercialize cannabinoid compounds as an alternative to long-term addictive opioid treatments.

The Company has also filed combination therapy formulations for the treatment of epilepsy and cachexia. About 50 million people worldwide are affected by epilepsy and about 1.3 million in the U.S. experience cachexia associated with cancer, MS, Parkinson's, HIV/AIDS and other progressive illnesses. Cancer-induced anorexia/cachexia is responsible for 20% of all cancer deaths. IGC-502 indicated for seizures and IGC-504 indicated for cachexia are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies.

IGC's strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio. "The development of combination therapies utilizing cannabis represents a large, unique opportunity in this emerging specialty-pharmaceutical sector. Securing FDA approval for combination therapy is believed to be significantly faster and less expensive than new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner," stated Ram Mukunda, CEO.

IGC has recently exited its legacy businesses and currently holds international investments in land and in a hotel project. An impressive and experienced team, led by Mr. Ram Mukunda, CEO, directs IGC.

Mr. Mukunda holds degrees in Electrical Engineering and Mathematics from the University of Maryland (UMD). He founded and served as Chairman and CEO of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec, the first pure play international long distance carrier, went public on NASDAQ. He has won a number of awards, including the 2013 University of Maryland International Alumnus of the year award. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering, and has served as Council Member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda and Dr. Krishna are the originators of all the IGC patent filings.

Dr. Ranga Krishna, Senior Advisor, is a Board Certified Neurologist with a sub specialty in Epilepsy surgery. He is the Director of Neurology at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College and the Director of Stroke Service at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College. He is the Medical Director and Chairman of Total Neuro Care, P.C. He is CEO of International Pharma Trials, Inc., which assists U.S. pharmaceutical companies perform Phase II clinical trials. Dr. Krishna is a member of several organizations, including the American Academy of Neurology and the Medical Society of the State of New York. He is also a member of the Medical Arbitration panel for the New York State Workers' Compensation Board and a Founding Member of the New York State Pain Society. Dr. Krishna was trained at New York's Mount Sinai Medical Center (1991-1994) and New York University (1994-1996). Dr. Krishna and Mr. Mukunda are the originators of all the IGC patent filings. Disclaimer

India Globalization Capital, Inc. Company Blog

India Globalization Capital, Inc. News:

IGC Acquires Exclusive Rights to THC-based treatment for Alzheimer’s Disease

India Globalization Capital, Inc. (NYSE: IGC) Taps Dr. Craig Cheifetz as Advisor for Clinical Trials of Cannabis-Based Combination Therapies

NetworkNewsWire Announces Editorial Discussing the Potential of Cannabis-Based Therapies for Pain Management

Epazz, Inc. (EPAZ)

The QualityStocks Daily Newsletter would like to spotlight Epazz, Inc. (EPAZ). Today, Epazz, Inc. closed trading at $0.0106, up 26.49%, on 15,003 volume with 4 trades. The stock’s average daily volume over the past 60 days is 155,853, and its 52-week low/high is $0.0061/$0.18.

Epazz, Inc. (EPAZ) is an enterprise-wide software company specializing in customized web applications for higher education institutions and the public sector. Through its proprietary BoxesOS applications, the company aims to create and maintain virtual communities that facilitate enhanced communication and provide up-to-date information and content in order to streamline the decision-making process for its clients. Epazz's BoxesOS also serves as a secure digital marketplace for various types of commerce, allowing the company to meet the increasing information technology demands of the 21st century.

In addition to its BoxesOS administrative services, Epazz offers a full end-user suite of solutions designed to maximize communication and functionality with full-featured web-based intranet software. Leveraging these offerings, the company's clients gain secure access and administrative control to customized features based on their unique needs. For businesses, the value of implementing these services can be tremendous. According to data from the McKinsey Global Institute, productivity improves by as much as 25 percent in organizations with connected employees. Studying just four commercial sectors (consumer packaged goods, retail financial services, advanced manufacturing and professional services), McKinsey estimates that the fiscal contributions of implementing effective intranet solutions could amount to as much as $1.3 trillion annually.

BoxesOS also allows companies to enhance communications with stakeholders by providing one-stop access to elegant, web-enabled information dashboards designed for specific user groups. Offering the ability to create unique dashboards for each stakeholder group addresses one of the most prominent issues facing workplace intranet projects – lack of engagement. Industry data suggest that properly engaging three core types of stakeholders, including executives, implementers and users, as well as the many sub-types within each of those groups, is key to the successful implementation of digital workplace solutions.

Outside of its business software solutions, Epazz is currently addressing a rising demand in the legal cannabis industry through its ZenaPay payment system. While banks remain hesitant regarding the legality of state-approved cannabis programs, dispensaries and related businesses have been compelled to operate on a cash-only basis, creating both security concerns and inconvenience for their customers. With ZenaPay, Epazz seeks to eliminate this issue by relying on the widely-used bitcoin cryptocurrency to provide an alternative to cash transactions. These efforts are particularly intriguing when studying the forward projections associated with marijuana sales. Per ArcView Market Research, North American marijuana sales grew by an unprecedented 30 percent in 2016 to $6.7 billion, and this figure is expected to top $20.2 billion by 2021.

Epazz is led by founder, chairman and CEO Shaun Passley, Ph.D. Founding the company in February 1999, Passley has been the guiding force behind Epazz's software and product development, as well as its continuing development of future products and services. Passley is joined on the Epazz management team by Raymond Kennedy, director of sales. Kennedy has more than two decades of experience in enterprise software sales, having previously served as marketing director for HCM, Inc., where he established six new sales territories and increased overall sales by more than 30 percent. Disclaimer

Epazz, Inc. Company Blog

Epazz, Inc. News:

Epazz, Inc. (EPAZ) Featured on MoneyTV with Donald Baillargeon, 6/2

Epazz, Inc. Reports Increase First Quarter Revenue and Profitability; Company is Focusing on Improving Fundamentals; Increasing Sales, Reducing Operational Expenses and Increasing Income

Epazz, Inc. Launches Zenapay.com, the Company's New Cannabis Payment System

InMed Pharmaceuticals, Inc. (IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.32, up 9.97%, on 734,951 volume with 265 trades. The stock’s average daily volume over the past 60 days is 1,042,279, and its 52-week low/high is $0.05/$0.72.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Raises $5.75 Million Through Underwritten Financing Including Full Exercise of the Over-Allotment Option

InMed Pharmaceuticals Files Provisional Patent Application for Ophthalmic Drug Delivery

InMed Pharmaceuticals' Unique Approach Featured in Forbes -- CFN Media

Monaker Group, Inc. (MKGI)

The QualityStocks Daily Newsletter would like to spotlight Monaker Group, Inc. (MKGI). Today, Monaker Group, Inc. closed trading at $2.50, up 2.04%, on 1,341 volume with 4 trades. The stock’s average daily volume over the past 60 days is 6,323, and its 52-week low/high is $1.71/$4.35.

Monaker Group, Inc. (MKGI) is a technology driven travel company focused on leveraging resources to become a significant presence in the fastest growing sector of the $1.3 trillion travel and tourism market. The company's flagship brand, NextTrip.com, is the industry's first and only real-time booking engine that features alternative lodging (vacation home rentals, resort residences and unused timeshare inventory), as well as a full selection of airlines, hotels, cruises, rental cars, tours and concierge services. These features are combined into a single, easy-to-use platform that gives travelers complete real-time control when planning and booking their vacations.

NextTrip.com takes an integrated approach to the needs of travelers by combining multiple booking solutions into a highly intuitive real-time booking platform. Since its launch in February 2016, NextTrip has already grown to more than 250,000 units of vacation rental inventory. Monaker currently has roughly 1 million additional alternative lodging units under contract that will soon be added to the platform. This will place NextTrip among the top three largest vacation rental inventories and rival industry peers, Airbnb and HomeAway, in the rapidly expanding alternative lodging market. Unlike the competition, which book by request which can take hours or days before a lodging owner confirms, NextTrip's platform books in real-time, similar to online hotel bookings.

Most NextTrip listings are in desirable locations in the U.S., the EU and the Caribbean with about 20% exclusive listings. Monaker expects rapid exclusive listing growth because, unlike the competition, Monaker doesn't charge a sign-up fee, just a commission upon booking. The competition charges both. Monaker even has a proprietary solution to unlock Timeshare and Fractional Share properties as rental inventory.

Through strategic partnerships and acquisitions Monaker is now positioned to be a major player in the travel and alternative lodging sector. In addition Monaker is also the parent to Maupintour and Voyage TV.

In business for 65 years, Maupintour still leads the tour industry in the creation of outstanding, unique itineraries and has the highest repeat rate in the tour industry. Maupintour's upscale luxury services create a unique blend with the various product offerings of NextTrip. Voyage TV has thousands of hours of travel footage shot in over 30 countries worldwide. These 15,000 video clips of hotels, resorts, cruise, and destination activities are a treasure trove for vacation travel marketing.

With an established portfolio of travel brands, and a proven record acquiring, consolidating and integrating companies, Monaker is building a diverse and exciting foundation to drive the company's future. According to data from the U.S. Travel Association, direct spending on leisure travel by domestic and international travelers topped $650 billion in 2015. When combined with the fact that roughly 64 percent of travel companies are still considered small businesses, Monaker's all-inclusive approach to vacation booking through NextTrip and Maupintour strategically positions it for sustainable growth moving forward.

Monaker is headquartered in South Florida with offices in California. The company is led by a seasoned management team with decades of applicable industry experience. Monaker's Chairman and Chief Executive Officer Bill Kerby has over 18 years of experience in the media and travel industries, as well as 10 years of experience in the financial industry. Disclaimer

Monaker Group, Inc. Company Blog

Monaker Group, Inc. News:

Monaker Launches NextTrip Website and Mobile App Featuring 1.2 Million Instantly Bookable Vacation Rental Properties

Monaker Reports Fiscal 2017 Year-in-Review, Highlighting Travel Industry's First Instant Booking, Customizable Alternative Lodging Booking Engine

Monaker Group to Attend the Oppenheimer Emerging Growth Conference in New York City on May 16th

National Waste Management Holdings, Inc. (NWMH)

The QualityStocks Daily Newsletter would like to spotlight National Waste Management Holdings, Inc. (NWMH). Today, National Waste Management Holdings, Inc. closed trading at $0.094, off by 0.95%, on 25,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 20,721, and its 52-week low/high is $0.06/$0.155.

National Waste Management Holdings, Inc. (NWMH) is a solid waste management company offering comprehensive solutions for full waste diversion along Florida's west coast and in upstate New York. With an established base of long-term partnerships with municipal, institutional, commercial and industrial customers, along with a successful acquisition strategy, National Waste has set its course to become a leading waste diversion company.

National Waste's 54-acre landfill facility located in Hernando, Florida, handles annual average disposals of roughly 240,000 cubic yards of construction debris annually. The site also offers an array of ancillary services such as roll-off dumpster services, mulching services and recycling. While the landfill facility is already permitted for future expansion, National Waste's growth strategy also calls for the opening of new satellite offices in counties and states that neighbor its existing operations.

In addition to increasing its geographic foothold, National Waste employs a strategic acquisition model to increase its overall market share. In 2015, the company acquired Gateway Rolloff Services LP and Waste Recovery Enterprises LLC, which are expected to generate a combined $3.8 million in annual revenue for National Waste moving forward. In the second quarter of 2016, National Waste added Sivart Services to its roster, creating an immediate source of additional revenue and expanding its foothold in the northeast area of New York.

Management has confirmed its interest in additional acquisition targets while demonstrating its ability to effectively integrate and organically grow the company's existing acquisition companies and maintain efficient operations. Disclaimer

National Waste Management Holdings, Inc. Company Blog

National Waste Management Holdings, Inc. News:

National Waste Management Holdings Inc. Reports Full-Year 2016 Results, Triple-Digit Revenue Growth

National Waste Management Holdings, Inc. Expands Territory with Acquisition of Burts Refuse, LLC

National Waste Management Holdings, Inc. (NWMH) Expands Market Reach in New York with Acquisition of Northeast Data Destruction and Recycling


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



MarketClub Analysis
(GTXI) +99.03%


(UMGP) +46.15%


(ICLD) +33.73%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251